Physician profile
Tet Toe
NPI 1710132733
$9,199.49
in general payments reported to CMS, 2019-2025
60 companies · $2,202 in 2025
The $2,202 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $548 · 2021: $1,523 · 2022: $1,460 · 2023: $1,444 · 2024: $1,617 · 2025: $2,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,246 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,245.79 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,445.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $815.36 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $801.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $718.85 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $687.28 | 2021-2025 | Zepbound, Mounjaro, Kisunla |
| Amgen INC. | $550.48 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.72 | 2020-2025 | Jardiance, Ofev |
| Abbvie INC. | $323.01 | 2021-2025 | Viberzi, Linzess, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.32 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $263.68 | 2019-2025 | |
| Exact Sciences Corporation | $260.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $221.55 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $199.66 | 2021 | |
| Currax Pharmaceuticals LLC | $161.11 | 2024-2025 | Contrave |
| Ibsa Pharma INC. | $158.23 | 2023-2025 | Tirosint, Tirosint, Licart |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tet Toe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.